Vol. 22/No. 17 | OncologyLive

Now Is the Time to Improve Diversity in Cancer Clinical Trials

September 27, 2021

Partner Perspective

Participating in a clinical trial is the most effective way to gain access to new and potentially better ways to treat cancer, yet we’ve seen a decrease in the number of African American and Hispanic patients participating in oncology trials in 2003 to 2016, compared with 1996 to 2002.

No-Cost Counseling Can Address Psychosocial Needs of Patients With Cancer

September 25, 2021

Feature Article

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

Lung Cancer Pioneer Paves Path for Future Innovation

September 24, 2021

OncologyLive

The achievements of Roman Perez-Soler, MD, include studies of anti-EGFR therapies and topoisomerase inhibitors, extensive research on liposomal delivery systems, and early work on patient-derived xenografts in mice.

Belumosudil Expands Treatment Options for Chronic GVHD

September 23, 2021

OncologyLive

Data from the phase 2 ROCKstar trial demonstrated that belumosudil induced clinically meaningful, durable responses in patients with chronic graft-vs-host disease, irrespective of previous treatment received, severity of disease, and number of organs involved.

Untangling Fact From Bias in the Age of Social Media and Mistrust

September 02, 2021

From the Editor

It is difficult to overstate the confusion associated with our nation’s messaging regarding a well-considered, rational, and scientifically based public health–focused approach to the current and future ramifications of the COVID-19 pandemic.